S&P 500   4,584.35 (+0.72%)
DOW   35,681.04 (+0.54%)
QQQ   381.86 (+0.49%)
AAPL   151.79 (+1.98%)
MSFT   321.90 (-0.39%)
FB   311.15 (-0.34%)
GOOGL   2,894.46 (-1.02%)
TSLA   1,060.86 (+2.22%)
AMZN   3,406.26 (+0.41%)
NVDA   247.05 (+1.04%)
BABA   169.39 (+0.09%)
NIO   39.52 (+0.53%)
CGC   13.01 (+1.80%)
GE   104.27 (+0.40%)
AMD   122.43 (+0.12%)
MU   69.29 (+1.54%)
T   25.54 (+1.92%)
F   16.99 (+9.54%)
ACB   6.92 (+1.17%)
DIS   169.65 (+0.06%)
PFE   43.22 (+0.58%)
BA   206.30 (-0.15%)
AMC   35.90 (+3.28%)
S&P 500   4,584.35 (+0.72%)
DOW   35,681.04 (+0.54%)
QQQ   381.86 (+0.49%)
AAPL   151.79 (+1.98%)
MSFT   321.90 (-0.39%)
FB   311.15 (-0.34%)
GOOGL   2,894.46 (-1.02%)
TSLA   1,060.86 (+2.22%)
AMZN   3,406.26 (+0.41%)
NVDA   247.05 (+1.04%)
BABA   169.39 (+0.09%)
NIO   39.52 (+0.53%)
CGC   13.01 (+1.80%)
GE   104.27 (+0.40%)
AMD   122.43 (+0.12%)
MU   69.29 (+1.54%)
T   25.54 (+1.92%)
F   16.99 (+9.54%)
ACB   6.92 (+1.17%)
DIS   169.65 (+0.06%)
PFE   43.22 (+0.58%)
BA   206.30 (-0.15%)
AMC   35.90 (+3.28%)
S&P 500   4,584.35 (+0.72%)
DOW   35,681.04 (+0.54%)
QQQ   381.86 (+0.49%)
AAPL   151.79 (+1.98%)
MSFT   321.90 (-0.39%)
FB   311.15 (-0.34%)
GOOGL   2,894.46 (-1.02%)
TSLA   1,060.86 (+2.22%)
AMZN   3,406.26 (+0.41%)
NVDA   247.05 (+1.04%)
BABA   169.39 (+0.09%)
NIO   39.52 (+0.53%)
CGC   13.01 (+1.80%)
GE   104.27 (+0.40%)
AMD   122.43 (+0.12%)
MU   69.29 (+1.54%)
T   25.54 (+1.92%)
F   16.99 (+9.54%)
ACB   6.92 (+1.17%)
DIS   169.65 (+0.06%)
PFE   43.22 (+0.58%)
BA   206.30 (-0.15%)
AMC   35.90 (+3.28%)
S&P 500   4,584.35 (+0.72%)
DOW   35,681.04 (+0.54%)
QQQ   381.86 (+0.49%)
AAPL   151.79 (+1.98%)
MSFT   321.90 (-0.39%)
FB   311.15 (-0.34%)
GOOGL   2,894.46 (-1.02%)
TSLA   1,060.86 (+2.22%)
AMZN   3,406.26 (+0.41%)
NVDA   247.05 (+1.04%)
BABA   169.39 (+0.09%)
NIO   39.52 (+0.53%)
CGC   13.01 (+1.80%)
GE   104.27 (+0.40%)
AMD   122.43 (+0.12%)
MU   69.29 (+1.54%)
T   25.54 (+1.92%)
F   16.99 (+9.54%)
ACB   6.92 (+1.17%)
DIS   169.65 (+0.06%)
PFE   43.22 (+0.58%)
BA   206.30 (-0.15%)
AMC   35.90 (+3.28%)
NASDAQ:INM

InMed Pharmaceuticals Stock Forecast, Price & News

$1.51
+0.01 (+0.67 %)
(As of 10/28/2021 09:58 AM ET)
Add
Compare
Today's Range
$1.49
$1.51
50-Day Range
$1.40
$2.51
52-Week Range
$1.38
$8.94
Volume
3,400 shs
Average Volume
246,718 shs
Market Capitalization
$14.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive INM News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


InMed Pharmaceuticals logo

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INM
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.83 per share

Profitability

Net Income
$-10.20 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$14.16 million
Next Earnings Date
12/16/2021 (Estimated)
Fiscal Year End
June 30
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

408th out of 1,372 stocks

Pharmaceutical Preparations Industry

192nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












InMed Pharmaceuticals (NASDAQ:INM) Frequently Asked Questions

Is InMed Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" InMed Pharmaceuticals stock.
View analyst ratings for InMed Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than InMed Pharmaceuticals?

Wall Street analysts have given InMed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InMed Pharmaceuticals?

InMed Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 66,800 shares, an increase of 189.2% from the September 15th total of 23,100 shares. Based on an average trading volume of 206,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.8% of the shares of the company are short sold.
View InMed Pharmaceuticals' Short Interest
.

When is InMed Pharmaceuticals' next earnings date?

InMed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, December 16th 2021.
View our earnings forecast for InMed Pharmaceuticals
.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its quarterly earnings data on Thursday, September, 23rd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.
View InMed Pharmaceuticals' earnings history
.

What price target have analysts set for INM?

1 brokerages have issued 1-year price objectives for InMed Pharmaceuticals' stock. Their forecasts range from $11.50 to $11.50. On average, they expect InMed Pharmaceuticals' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 666.7% from the stock's current price.
View analysts' price targets for InMed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 57, Pay $423.76k)
  • Mr. Bruce S. Colwill C.A., CPA, CA, CFO & Corp. Sec. (Age 56, Pay $313.13k)
  • Ms. Alexandra Diane-Janet Mancini, Sr. VP of Clinical & Regulatory Affairs (Age 68, Pay $308.19k)
  • Dr. Eric Chih-Hsien Hsu, Sr. VP of Preclinical R&D (Age 51, Pay $248.99k)
  • Mr. Michael Woudenberg P.Eng., VP of Chemistry, Manufacturing & Controls (Age 54, Pay $238.14k)
  • Dr. Sazzad Hossain, Co-Founder
  • Mr. Brendan Payne, Director of Investor Relations
  • Mr. Richard Hoy, VP of Sales & Marketing
  • Dr. Ado Muhammad, Sr. Consultant of Medical Affairs

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "INM."

How do I buy shares of InMed Pharmaceuticals?

Shares of INM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMed Pharmaceuticals' stock price today?

One share of INM stock can currently be purchased for approximately $1.50.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals has a market capitalization of $14.07 million. The company earns $-10.20 million in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does InMed Pharmaceuticals have?

InMed Pharmaceuticals employs 20 workers across the globe.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at 604-669-7207 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.